Basic Information
Cantargia is a Swedish biotechnology company focused on developing drugs for the treatment of various cancers and inflammatory/autoimmune diseases. Our development pipeline includes the candidate product nadunolimab (CAN04), which is in Phase IIa clinical trials, CAN10, which is in the preclinical stage, and our development project CANxx.
Cantargia AB
Skåne,Sweden
less than 15 people
January 01, 2010
info@cantargia.com
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios